GALT Galectin Therapeutics

Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2020 Annual Meeting of Stockholders to be held on Thursday, December 3, 2020, beginning at 11:00 a.m. EST.

The Annual Meeting of Stockholders and webcast can be accessed via .

Please log in approximately 10 minutes before the event to ensure a timely connection.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation for NASH cirrhosis by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at .

Contact

Jack Callicutt, Chief Financial Officer

(678) 620-3186

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02



EN
01/12/2020

Underlying

GALTGalectin Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galectin Therapeutics

 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Reports Financial Results for the Quarter Ended ...

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in patient...

August 14, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Announces New $10 Million Credit Line from Richa...

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, announced today it entered into a new $10 million unsecured line of credit facility with Richard E. Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder. “Belapectin has the potenti...

July 9, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin ...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hy...

June 10, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Reports Financial Results for the Quarter Ended ...

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week a...

May 15, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Presented NAVIGATE Trial Results at the European...

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis....

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch